Collectively, our results show that 753b is significantly more potent than DT2216, navitoclax, and the DT2216 + venetoclax combination in killing BCL-xL/2 co-dependent SCLC cells via degradation of both the proteins. The gene discussed is BCL2L1; the disease is small cell lung carcinoma.